Get started
Vir Biotechnology, Inc.Vir Biotechnology, Inc.Vir Biotechnology, Inc.

Vir Biotechnology, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

VIR chart


Full chart

VIR upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪1.32 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−3.92 USD
Net income (FY)
‪−615.06 M‬ USD
Revenue (FY)
‪86.18 M‬ USD
Shares float
‪88.08 M‬
Beta (1Y)
0.64

Employees


Employees (FY)
587
Change (1Y)
+11 +1.91%
Revenue / Employee (1Y)
‪146.81 K‬ USD
Net income / Employee (1Y)
‪−1.05 M‬ USD

About Vir Biotechnology, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Marianne de Backer
Website
vir.bio
Headquarters
San Francisco
Founded
2016
FIGI
BBG00H2QQ8T5
Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

VIR news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of VIR is 9.60 USD — it has decreased by −1.74% in the past 24 hours. Watch Vir Biotechnology, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Vir Biotechnology, Inc. stocks are traded under the ticker VIR.
VIR stock has risen by 34.45% compared to the previous week, the month change is a 31.51% rise, over the last year Vir Biotechnology, Inc. has showed a 10.98% increase.
We've gathered analysts' opinions on Vir Biotechnology, Inc. future price: according to them, VIR price has a max estimate of 110.00 USD and a min estimate of 10.00 USD. Watch VIR chart and read a more detailed Vir Biotechnology, Inc. stock forecast: see what analysts think of Vir Biotechnology, Inc. and suggest that you do with its stocks.
VIR reached its all-time high on Jan 27, 2021 with the price of 141.01 USD, and its all-time low was 7.12 USD and was reached on Oct 1, 2024. View more price dynamics on VIR chart.
See other stocks reaching their highest and lowest prices.
VIR stock is 3.48% volatile and has beta coefficient of 0.64. Track Vir Biotechnology, Inc. stock price on the chart and check out the list of the most volatile stocks — is Vir Biotechnology, Inc. there?
Today Vir Biotechnology, Inc. has the market capitalization of ‪1.32 B‬, it has increased by 3.40% over the last week.
Yes, you can track Vir Biotechnology, Inc. financials in yearly and quarterly reports right on TradingView.
Vir Biotechnology, Inc. is going to release the next earnings report on Feb 20, 2025. Keep track of upcoming events with our Earnings Calendar.
VIR earnings for the last quarter are −1.56 USD per share, whereas the estimation was −1.05 USD resulting in a −48.22% surprise. The estimated earnings for the next quarter are −0.86 USD per share. See more details about Vir Biotechnology, Inc. earnings.
Vir Biotechnology, Inc. revenue for the last quarter amounts to ‪2.38 M‬ USD, despite the estimated figure of ‪5.54 M‬ USD. In the next quarter, revenue is expected to reach ‪8.14 M‬ USD.
VIR net income for the last quarter is ‪−213.72 M‬ USD, while the quarter before that showed ‪−138.38 M‬ USD of net income which accounts for −54.44% change. Track more Vir Biotechnology, Inc. financial stats to get the full picture.
No, VIR doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 10, 2024, the company has 587.00 employees. See our rating of the largest employees — is Vir Biotechnology, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Vir Biotechnology, Inc. EBITDA is ‪−524.78 M‬ USD, and current EBITDA margin is −744.43%. See more stats in Vir Biotechnology, Inc. financial statements.
Like other stocks, VIR shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Vir Biotechnology, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Vir Biotechnology, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Vir Biotechnology, Inc. stock shows the neutral signal. See more of Vir Biotechnology, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.